Ph2 or Ph3 placebo-controlled comparative clinical trials with sufficient data quoted in interview forms of 24 approved drugs

(n = 68)b

Stage 2:

Clinical trial selection

No clinical trial data in public (n = 1)

Stage 1:

Drug selection

Approved drugs for type 2 diabetes in Japan with clinical trial data in public which were classified #396 in Japanese therapeutic code (n = 25)

Clinical trials without sufficient data of Japanese patients for the analysis (n = 20)

Ph2 or Ph3 clinical trials quoted in interview forms of 25 approved drugs (n = 169)

Not comparative clinical trials or extension trials (n = 71)

Ph2 or Ph3 comparative clinical trials quoted in interview forms of 25 approved drugs (n = 98)

Not placebo-controlled trials (n = 10)

Ph2 or Ph3 comparative clinical trials with sufficient data quoted in interview forms of 24 approved drugs (n = 78)a

Approved drugs for type 2 diabetes in Japan which were classified #396 in Japanese therapeutic code (n = 26)

aData used for analyses of baseline HbA1c and changes in HbA1c.

bData used for analysis of effect size for HbA1c. Figure S1 Flowchart of data collection